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Abstract
Tissue plasminogen activator, a serine protease encoded by the PLAT gene is present in the trabecular meshwork
(TM) and other ocular tissues and has been reported to be downregulated by treatment with steroids in vitro. Steroids
are known to cause changes in outflow facility of aqueous humor in many species. In the present study, we tested
whether overexpression of PLAT can prevent and/or reverse the outflow facility of mouse eyes treated with steroids.
Animals received bilateral injection with 20 µl of triamcinolone acetonide (TA) (40mg/ml) suspension
subconjunctivally to induce outflow facility changes. Some animals received unilateral intracameral injection with 2 µl
of adenoviral suspension [3-4x1012 virus genomes per milliliter (vg/ml)] carrying sheep PLAT cDNA (AdPLAT) either
concurrently with TA injection or one week after TA injection, whereas others received bilateral intracameral injection
with 2µl of adenoviral suspension (9x1012 vg/ml) carrying no transgene (AdNull) concurrently with TA injection.
Animals were sacrificed one week after AdPLAT or AdNull treatment. Endogenous mRNA expression levels of
mouse PAI-1 and MMP-2, -9 and -13 were also measured using qRT-PCR. Outflow facility one week after AdPLAT
administration was increased by 60% and 63% respectively for animals that had not or had been pretreated with
steroids. Overexpression of PLAT significantly upregulated expression of PAI-1, MMP-2, -9 and -13 compared to the
levels found in TA only treated eyes. These findings suggest that overexpression of PLAT in TM of mouse eyes can
both prevent and reverse the decrease in outflow facility caused by steroid treatment and is associated with
upregulation of MMPs.
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Introduction
Tissue plasminogen activator (tPA) is a serine protease,
localized in the uveal microvasculature, corneal endothelium,
corneal epithelium and the trabecular meshwork (TM) of the
eye [1]. tPA enzymatic activity has also been measured in
aqueous humor (AH) in dog, calf, monkey [2] and human eyes
[3]. It catalyzes the conversion of plasminogen (an inactive
proenzyme of the fibrinolytic system), to plasmin, a protease
involved in the degradation of a variety of proteins. Plasmin is a
critical component of the fibrinolytic pathway but also activates
several pro matrix-metalloproteinases (pro-MMPs) to their
active form [4]. MMPs are a family of zinc containing proteases
which play an important role in the degradation of extracellular
matrix (ECM) proteins. It has been suggested that these
enzymes are necessary to maintain normal (AH) outflow.
Decrease in these enzymes could result in the accumulation of
ECM components in the TM leading to alteration in aqueous
outflow [5,6]. The effect of tPA-mediated MMP activation is
inhibited either at the level of tPA by specific inhibitors
[plasminogen activator inhibitor-1 (PAI-1) and plasminogen
activator inhibitor-2 (PAI-2)] or at the level of plasmin mainly by
alpha 2-antiplasmin [7]. Proper balance between tPA and its
inhibitors is critical for homeostatic maintenance.
Glucocorticoids (GC) are well known to cause an increase in
intraocular pressure (IOP) which is a major risk factor for
glaucoma [8,9]. Approximately 30-40% of patients treated with
GC topically or systemically develop ocular hypertension. The
severity of disease depends on the GC potency,
pharmacokinetics, duration of treatment and route of
administration and steroid responders have a higher
predisposition for developing glaucoma than nonresponders.
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Moreover, nearly 90% of patients with preexisting primary
open-angle glaucoma (POAG) respond to steroid treatment
with further elevation of IOP [10–12].
Although the exact mechanism by which steroid induces
elevation in IOP is not well understood, chronic steroid
treatment results in increased aqueous humor outflow
resistance and is associated with morphological and
biochemical changes in the TM [13–15]. These changes
include inhibition of expression and activity of MMPs and
downregulation of PLAT, the gene encoding for tPA [16–18].
The inhibition of those molecules can be what causes decrease
in the breakdown of the ECM of the TM resulting in increased
outflow resistance.
To test this hypothesis, we overexpressed PLAT in the TM,
utilizing a recently introduced mouse model of steroid induced
outflow facility change [19]. We also analyzed by qPCR the
levels of PAI-1 and MMPs 2, 9 and 13 to determine whether
any effects are caused via MMPs.
Materials and Methods
Animals
Three-month old female mice of C57BL/6 strain were used in
this study. The animals were kept under a 12-hour light/12-hour
dark cycle and fed ad libitum. This study was carried out in
strict accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research and was approved
by the Institutional Animal Care and Use Committee (IACUC).
The protocol was approved by the Committee on the Ethics of
Animal Experiments of the State University of New York
(SUNY) Downstate Medical Center, Brooklyn, NY.
Adenoviral vector construction
The full coding region of the sheep PLAT mRNA (1.8 kb)
(NCBI reference sequence number XM_004021803.1) was
amplified using cDNA synthesized from RNA extracted from
sheep brain tissue. Amplification was performed using Phusion
High-Fidelity PCR Master Mix with HF Buffer (NEB Inc,
Ipswich, MA, USA). Primer sequences used for amplification
were as follows; forward primer: 5’-
CTGAAGACAACGCCTCTGGAGGA-3’ and reverse primer: 5’-
TGGGAGAAGCGGGGTCTCTGTG-3’. PCR product was
subjected to sequence analysis to confirm the sheep PLAT
mRNA sequences. The expression cassette was constructed
by placing amplified and gel purified PLAT cDNA adjacent to a
human histone B (H2B) tagged fluorescent reporter gene
(mCherry) with internal ribosome entry site (IRES) in a suitable
cloning vector (Figure 1A). The expression cassette was then
subcloned downstream of a CMV promoter at the multiple
cloning site of the shuttle vector [20] (Figure 1B). All cloning
reactions were performed using In-Fusion HD cloning kit
(Clontech, Mountain View, CA, USA) according to the
manufacturer’s protocol.
Adenovirus generation and titration
Adenovirus vectors carrying transgene (AdPLAT) and no
transgene (AdNull) were generated by homologous
recombination using the AdEasy Adenoviral Vector System
(Stratagene, La Jolla, CA) [21]. Briefly, shuttle vectors
containing transgene or no transgene were linearized with
PmeI and electroporated into BJ5183-Ad1 cells for the
recombination with the adenovirus backbone plasmid
(pAdEasy1) according to manufacturer’s directions. The
Figure 1.  Map of AdPLAT Construct.  PLAT gene was amplified from cDNA synthesized from RNA extracted from sheep brain
tissue. The expression cassette (A) was constructed by placing amplified and gel purified PLAT cDNA adjacent to a human histone
B (H2B) tagged fluorescent reporter gene (mCherry) with internal ribosome entry site (IRES) in a suitable cloning vector. The
expression cassette was then subcloned downstream of a CMV promoter at the multiple cloning site of the shuttle vector (B) and
used to generate adenovirus (AdPLAT).
doi: 10.1371/journal.pone.0072447.g001
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resultant vectors were amplified in E. coli competent cells
XL10-gold (Stratagene, La Jolla, CA), purified, linearized with
PacI and transfected into early-passage QBI-HEK 293A cells
(Qbiogene, Montreal, Canada) for the production of the
recombinants. High-titer viral stocks were obtained by
propagation in the same cells and purification by double
banding CsCl density centrifugation [21]. The collected viral
band was desalted with NAP-5 columns (GE Healthcare,
Piscataway, NJ) equilibrated with virus vehicle (0.01 M Tris pH
7.4, 1 mM MgCl2, 10% glycerol), aliquoted and stored at -80oC.
Physical particles of adenovirus were titrated as virus
genomes per milliliter (vg/ml) by real-time PCR after extraction
of the viral DNA using the DNeasy tissue kit (Qiagen, Valencia,
CA). Viral infectivity was measured as infectious units/ml
(IFU/ml) with a rapid titer kit (AdenoX; Clontech, Mountain
View, CA) containing an antibody specific to the adenovirus
hexon capsid protein produced only in infected cells [21].
Steroid and adenoviral treatment
All animals received bilateral injection with 20 µl of
triamcinolone acetonide (TA) (40mg/ml) suspension
subconjunctivally using a Hamilton syringe with a 26-gauge
needle. Animals were then divided into three groups (Figure 2):
1) animals that received unilateral intracameral injection with 2
µl of AdPLAT (3-4x1012 vg/ml) concurrently with the TA
injection while the contralateral eye remained uninjected, 2)
animals that received bilateral intracameral injection with 2 µl of
AdNull (9 x1012 vg/ml) concurrently with TA treatment, and 3)
animals that received unilateral intracameral injection with 2 µl
of AdPLAT one week after TA injection while the contralateral
eye remained uninjected. The intracameral injections were
performed using a Hamilton syringe with a 36-gauge stainless
steel needle (WPI Inc, Sarasota, FL, USA). Animals were
sacrificed one week after AdPLAT or AdNull treatment. All
injections were performed under intraperitoneal anesthesia with
ketamine/xylazine mix and topical anesthesia with 0.5%
proparacaine. An additional group of naïve untreated mice was
used for RNA extraction and served as naïve controls to
determine ΔΔCt by qRT-PCR (ΔΔCt is defined in subsection
‘quantitative real-time PCR’, see below).
IOP measurement
IOP was measured in mice preterminally with a rebound
tonometer [22]. The animals were held in a custom-made
restraint that does not compress the chest or neck while IOP is
measured [23]. IOP measurements were performed after
application of 0.5% proparacaine topical anesthesia. Five
measurements were obtained per eye and averaged. IOP
measurements were performed between 10 AM and 12 PM, to
minimize the effect of diurnal IOP variation.
Outflow facility determination
The animals were sacrificed by cervical dislocation under
deep surgical anesthesia. The eyes were immediately
enucleated and used for the determination of outflow facility.
Outflow facility was determined using a constant flow method.
Eyes were initially perfused at a flow rate of 0.1 µl/min and the
system was allowed to run for 30-40 minutes to achieve stable
baseline pressure. Flow rate was then increased sequentially
to 0.13, 0.15, 0.2, 0.25, 0.3 µl/min. Pressures were recorded
either continuously using a chart recorder or intermittently
(every 5 minutes) using a digital recorder. The pressure
Figure 2.  Experimental Design.  12 week-old C57BL/6 female mice received bilateral injections with 20 ul of triamcinolone
acetonide (TA) suspension subconjunctivally. Animals were then divided into three treatment groups: 1) animals that also received
unilateral intracameral injection with 2 ul of AdPLAT concurrently with TA injection while the contralateral eye remained uninjected,
2) animals that received bilateral intracameral injection with 2 ul of AdNull concurrently with TA injection, and 3) animals that
received unilateral intracameral injection with 2 ul of AdPLAT one week after TA injection while the contralateral eye remained
uninjected. Animals were sacrificed for outflow facility determination one week after AdPLAT or AdNull treatment.
doi: 10.1371/journal.pone.0072447.g002
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readings at steady state at each flow rate were plotted and the
slope of the regression line was used to calculate outflow
facility as described previously [19].
Visualization of mCherry expression under fluorescent
microscope
After perfusion, mCherry expression in the TM was
determined in all AdPLAT-injected eyes. The eyes were
dissected on ice to isolate a rim of tissue containing the TM by
removing most of the cornea, iris, and ciliary body. Flat mounts
of the rims containing TM were observed in an epifluorescent
microscope equipped with the appropriate filter sets to visualize
mCherry expression. After observation, dissected rims were
immediately immersed in RNA stabilizing agent (RNAlater,
Ambion; Invitrogen, Carlsbad, CA).
Tissue collection and Isolation of RNA
All perfused eyes were immersed in RNA stabilizing agent at
4°C overnight and stored at -20°C until RNA extraction. The
eyes were dissected on ice in the presence of RNA stabilizing
agent to isolate a rim of tissue containing the TM as described
above. Rims containing TM from eyes of the same analysis
group were pooled together (four at a time) to achieve sufficient
amount of RNA for analysis. The rims were homogenized and
total RNA was extracted using TRIzol reagent (Gibco/
Invitrogen, Carlsbad, CA). Briefly, the tissue was homogenized
in TRIzol and chloroform was added to separate proteins from
RNA. After centrifugation, the RNA-containing supernatant was
aspirated. The RNA was precipitated with isopropanol, washed
with 75% ethanol, and resuspended in nuclease-free water.
RNA concentrations were determined with a
spectrophotometer (Nanodrop, Thermo Scientific, Wilmington,
DE) and the 260/280-nm absorbance ratio calculated to
determine RNA purity.
Quantitative real-time PCR
The RNA samples were reverse transcribed with random
hexamers to cDNA using a reverse transcription kit (Quantitect;
Quiagen, Valencia, CA), in accordance with the manufacturer’s
instructions. Quantitative real-time PCR (qRT-PCR) was
performed using a commercial kit (SYBR Green RT-PCR
Reagents Kit; Applied Biosystems, Carlsbad, CA). qRT-PCR
was carried out in a ABI PRISM 7900HT sequence detector
(Applied Biosystems, Carlsbad, CA). The mRNA expression of
sheep PLAT transgene (allowing us to measure PLAT
transgene transcription), and mouse endogenous matrix
metalloproteinase-2 (MMP-2), matrix metalloproteinase-9
(MMP-9), matrix metalloproteinase-13 (MMP-13) and
plasminogen activator inhibitor 1 (PAI-1) in the TM were
investigated in eyes from all experimental groups. The mouse
specific primer sequences used are listed in Table 1. Relative
quantification of gene expression was performed using the
standard curve method. Relative fold change was calculated by
the formula 2-ΔΔCt where Ct is defined as the cycle at threshold.
ΔCt is defined as the difference in mean of Ct values derived
from the target gene and the 18S gene (an internal control) and
ΔΔCt is defined as ΔCt of the normalized assayed genes in the
treated samples minus ΔCt of normalized assayed genes in the
naïve control samples. Fold changes were compared to 1 by
single group t-test.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(3.03) software. The differences in means were analyzed using
one way analysis of variance (ANOVA) followed by Tukey’s
multiple comparison test. Values of p<0.05 were considered to
be statistically significant.
Results
PLAT expression in AdPLAT injected eyes
To verify PLAT expression, mCherry expression was
visualized on flat-mounted TM immediately after outflow facility
determination. mCherry expression was limited to the TM and
distributed uniformly along the entire length of the TM. No
mCherry expression was seen in the cornea or other tissues
within the anterior segment (Figure 3A). Some AdPLAT
injected eyes however, showed minimal (just one or two
mCherry positive cells per eye) or no mCherry expression in
the TM (Figure 3B). These eyes were analyzed as a separate
group (TA+/-AdPLAT) from eyes which showed robust mCherry
expression (TA+/+ AdPLAT). No mCherry expression was
observed in naïve control eyes (Figure 3C). To further confirm
PLAT expression and to determine whether expression also
occurs in eyes without significant visible mCherry expression,
qPCR was performed on RNA from TM tissue. The expression
of sheep PLAT gene was observed in the TM of eyes receiving
AdPLAT with robust mCherry expression but not in similarly
treated eyes with minimal or no mCherry expression. TA alone
injected eyes (TA) also showed no ovine PLAT gene
expression by qPCR (Figure 3D).
Effect of AdPLAT on IOP of TA injected eyes
In animals that received AdPLAT concurrently or one week
after TA injection, no significant difference was observed in IOP
among eyes injected with TA and AdPLAT showing robust
mCherry expression, eyes injected with TA and AdPLAT
Table 1. Primer sequences of genes analyzed by qRT-
PCR.
Gene Primer Sequence (5’- 3’) Size (bp)
PLAT forward CAGTGCCCAGAAGGGTTCAT 249
 reverse GTAGCACCAGGGCTTTGAGT  
MMP-2 forward GACCATGCGGAAGCCAAGAT 122
 reverse CCAGGTCAGGTGTGTAACCA  
MMP-9 forward GTCCAGACCAAGGGTACAGC 195
 reverse GCCTTGGGTCAGGCTTAGAG  
MMP-13 forward AGTGCCTGATGTGGGTGAAT 161
 reverse GTGGTGTCACATCAGACCAGA  
PAI-1 forward GCTGTAGACGAGCTGACACG 218
 reverse TAGGGCAGTTCCACAACGTC  
18S forward AGTCCCTGCCCTTTGTACACA 69
 reverse GATCCGAGGGCCTCACTAAAC  
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showing minimal or no mCherry expression, and contralateral
eyes injected with TA alone. IOP was also not significantly
different between eyes injected with TA and AdNull (TA
+AdNull) and eyes from all other groups. All eyes appeared
normal on slit lamp examination.
PLAT prevents and reverses decrease in outflow
facility caused by TA
In animals injected with AdPLAT concurrently with TA, the
mean ± standard deviation (SD) outflow facility in AdPLAT
injected eyes showing robust mCherry expression (TA+/+
AdPLAT) (n=12), AdPLAT injected eyes showing minimal or no
mCherry expression (TA+/-AdPLAT) (n=8), and contralateral
Figure 3.  mCherry expression in flat mounts of TM in AdPLAT-injected Eyes.  Flatmount of anterior segments of mouse eyes
from (A) animal injected with AdPLAT that showed robust mCherry expression (TA+/+ AdPLAT) (B) animal with minimal mCherry
expression despite injection with AdPLAT (TA+/-AdPLAT), and (C) treatment-naïve mouse. (D) qRT-PCR quantification of
transgenic PLAT expression in mouse eyes. Levels of PLAT are undetectable in all eyes except those showing robust mCherry
expression (TA+/+ AdPLAT). CP = ciliary processes, TM = trabecular meshwork. Arrows indicate mCherry-positive cells.
doi: 10.1371/journal.pone.0072447.g003
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eyes injected with TA alone (TA) (n=22) was 0.0097 ± 0.0033,
0.0062 ± 0.0022, and 0.0060 ± 0.0025, respectively, while eyes
that received both TA and AdNull concurrently (TA+AdNull)
(n=30) had outflow facility of 0.0071 ± 0.0023. TA+/+AdPLAT
eyes had a 60%, 56%, and 35% increase in outflow facility
compared to TA, TA+/-AdPLAT, and TA+AdNull eyes,
respectively. One-way ANOVA revealed significant difference
(p<0.01) in outflow facility among TA+/+ AdPLAT, TA+/-
AdPLAT, TA and TA+AdNull eyes. Post-hoc analysis showed a
significant increase in outflow facility of TA+/+ AdPLAT eyes
compared with TA+/-AdPLAT eyes (p<0.05), TA eyes (p<0.01),
and eyes receiving both TA and AdNull (p<0.05). No significant
difference in outflow facility was detected between TA+AdNull
eyes, TA eyes or TA+/-AdPLAT eyes (Figure 4).
In animals receiving AdPLAT one week after TA injection,
the mean ± SD outflow facility in TA+/+ AdPLAT (n=6), TA+/-
AdPLAT (n=11) and TA (n=24) eyes was 0.0109 ± 0.0026,
0.0062 ± 0.0027, and 0.0067 ± 0.0028 respectively. TA+/
+AdPLAT eyes in this treatment arm had a 75% and 63%
increase in outflow facility compared to TA+/-AdPLAT eyes and
TA eyes respectively. Outflow facility was significantly different
in TA+/+ AdPLAT eyes, TA+/-AdPLAT eyes and TA eyes
(ANOVA, p<0.01). Post hoc analysis revealed a significant
increase (p<0.01) in outflow facility of TA+/+ AdPLAT eyes
compared with TA+/-AdPLAT and TA eyes. There was no
significant difference in outflow facility among eyes receiving
TA alone and TA+/-AdPLAT eyes (Figure 5).
PLAT induces expression of PAI-1, MMP-2, MMP-9 and
MMP-13
PAI-1and MMP-2 expression was significantly different
(ANOVA, p<0.01 and p<0.001 respectively) among TA+/+
AdPLAT, TA+/-AdPLAT and TA treated eyes that had been
treated with TA one week prior to AdPLAT administration. Post
hoc analysis revealed that TA+/+ AdPLAT eyes had
significantly higher (p<0.01) relative PAI-1 expression
compared to TA+/-AdPLAT eyes and TA eyes (Figure 6A). The
Figure 4.  Outflow facility in TA and AdPLAT concurrently treated mouse eyes.  Mean ± SD outflow facility in eyes receiving
TA alone (TA, n=22), eyes injected with AdPLAT showing robust mCherry expression (TA+/+ AdPLAT, n=12), eyes injected with
AdPLAT showing minimal or no mCherry expression (TA+/-AdPLAT, n=8), and eyes injected with AdNull (TA+AdNull, n=30). Group
means are significantly different (ANOVA, p<0.01). Asterisks indicate significant differences on post hoc analysis, *p<0.05,
**p<0.01.
doi: 10.1371/journal.pone.0072447.g004
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expression of MMP-2 was also significantly higher (p<0.001) in
the TM of TA+/+ AdPLAT eyes compared to eyes from TA+/-
AdPLAT and TA groups (Figure 6B). Compared to TA-alone
injected eyes, the expression of PAI-1 was increased by 3.1 ±
1.1-fold and expression of MMP-2 was increased by 20.2 ±
11.6-fold in TA+/+ AdPLAT eyes.
MMP-9 and MMP-13 expression was also upregulated in TA
+/+ AdPLAT eyes. However because their expression levels
were beyond the detection limit in the naïve control group as
well as in all other groups, the data could not be subjected to
statistical analysis (Figure 6 C and D).
Discussion
Glucocorticoid-induced IOP elevation has been an
increasingly big problem with the increased use of intraocular
steroids. Patients with POAG receiving various formulations of
GC therapy have been shown to be particularly prone to
developing further elevation in IOP [9,10]. The mechanism by
which GCs cause increase in IOP is through increased outflow
resistance in the TM, which is associated with alteration in
ECM turnover [24,25]. ECM turnover is in part maintained by
the regulation of proteolytic enzymes of the fibrinolytic pathway
and MMP family [5,6]. GCs have been shown to alter these
pathways in the TM and other ocular tissues by inhibiting the
expression and activity of MMP and PLAT [16–18]. We
previously have shown that PLAT is downregulated by ~40% in
the TM of bovine eyes treated with steroid (unpublished data).
On the basis of this evidence, we tested whether PLAT
upregulation can prevent and/or reverse GC-induced outflow
resistance changes.
We have recently established a mouse model of steroid-
induced change in outflow facility in which subconjuntival
injection of triamcinolone acetonide (TA) decreases outflow
facility after one week of injection [19]. In the present study we
used adenoviral vector carrying sheep PLAT cDNA to
upregulate PLAT expression as adenoviruses have been
shown to transfect TM cells very efficiently [26,27].
We used the sheep PLAT gene as the induced transgene.
Sheep tPA shares a 78% similarity with the mouse tPA and
Figure 5.  Outflow facility of eyes receiving AdPLAT one week after TA injection.  Mean ± SD outflow facility in eyes receiving
TA alone (TA, n=24), eyes injected with AdPLAT showing robust mCherry expression (TA+/+ AdPLAT, n=6), and eyes injected with
AdPLAT showing minimal or no mCherry expression (TA+/-AdPLAT, n=11). Group means are significantly different (ANOVA,
p<0.01). Asterisks indicate significant differences on post hoc analysis, **p<0.01.
doi: 10.1371/journal.pone.0072447.g005
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similarly the PLAT genes show a 78% similarity at the cDNA
level. This difference in combination with the primers that were
designed specifically for the sheep PLAT allows us to measure
PLAT transgene transcription after RNA extraction of mouse
angle tissues.
In addition we constructed our expression cassette to include
a red fluorescent protein under IRES control. This has enabled
us to visually observe whether the transgene was expressed in
the TM. Despite the high concentration of adenovirus used in
this experiment we were surprised to find that a number of
Figure 6.  Gene expression changes.  Normalized fold change (mean ± SD) of (A) PAI-1 and (B) MMP-2 expression and
normalized fold difference of (C) MMP-9 and (D) MMP-13 expression in TA eyes (n=10), TA+/+ AdPLAT eyes (n=9), and TA+/-
AdPLAT eyes (n=10) from animals receiving AdPLAT one week after TA injection. Group means are significantly different (ANOVA
PAI-1, p<0.01, MMP-2, p<0.001). Asterisks indicate differences on post hoc analysis, **p<0.01, ***p<0.001. No mRNA was detected
for MMP-9 and MMP-13 in the TA or TA+/-AdPLAT groups.
doi: 10.1371/journal.pone.0072447.g006
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eyes did not show any evidence of mCherry expression in the
anterior chamber (AC). In addition in eyes that showed
mCherry expression in the TM no other tissues showed similar
expression in the AC. This is in contrast to other adenoviruses
(with different transgenes) we have tested (data not shown)
that often show extensive expression in the corneal
endothelium and may indicate quick silencing of the transgene
production in these tissues. Nonetheless to ensure that
mCherry expression reflects PLAT expression we performed
qPCR in tissues from both eyes that had significant as well as
eyes with negligible mCherry expression. qPCR results
confirmed that PLAT expression is undetectable in eyes
without mCherry expression. Based on this finding, we
analyzed eyes injected with AdPLAT as separate groups
depending on their TM mCherry expression.
We initially asked whether adenovirus induced-PLAT
overexpression can prevent outflow facility changes in mice. To
address this question we administered AdPLAT concurrently
(immediately after) subconjunctival TA injection. Adenoviral
transgene expression occurs within 48-72 hours [27]
(unpublished data) and thus precedes the changes in outflow
facility that occur in mice after approximately one week of TA
treatment. Determination of outflow facility at one week after
TA and AdPLAT administration revealed that sheep PLAT
overexpression in the mouse TM leads to a 60% increase in
outflow facility. As expected this increase in outflow facility did
not cause a significant reduction in IOP [19]. Similarly,
administration of AdPLAT one week after TA injection
increased outflow facility one week later, by 63%. This finding
confirms that PLAT overexpression is not only sufficient to
prevent outflow facility changes induced by steroids but can
just also reverse the changes in this animal model.
In an effort to understand how tPA causes these changes in
outflow facility we examined the expression levels of some of
the genes that regulate the tPA pathway, as well as known
effectors of tPA actions. As the amount of tissue that can be
collected from a single mouse eye is rather limited for multiple
PCR reactions we had to pool four eyes per group of genes
analyzed. This could have resulted in a slight decrease of the
variability between individual eyes. Despite this we were able
to determine that PAI-1 expression was upregulated in eyes
overexpressing sheep PLAT. Since tissue dissection inevitably
contained some ciliary body in all eyes it is unclear whether
PAI-1 was actually upregulated in the TM or in the ciliary
processes (CPs). It is known that PAI-1 is produced in the CPs
and secreted in the aqueous humor [28]. However, PAI-1
mRNA has also been detected in cultured human TM cells [29].
Prior reports have shown that PAI-1 levels are increased in
patients with chronic open angle glaucoma [30], making the
results of the current study potentially relevant to a wider
number of glaucomas in addition to steroid-induced IOP
elevation. In the present study we believe that PAI-1
upregulation is part of a feedback loop that attempts to control
excessive tPA activation. PLAT overexpression seems to also
upregulate expression of a number of pro-MMPs. We
specifically show that it results in an eight-fold upregulation of
MMP-2 and additional upregulation of MMP-9 and -13 which
now become detectable.
MMPs are a family of zinc- and calcium-dependent enzymes
able to degrade ECM components. In particular, two members
of the MMP family, MMP-2 (gelatinase A) and MMP-9
(gelatinase B), are able to degrade major components of ECM
like collagens type IV, V, VII and X, laminins, and fibronectin.
Previous studies have shown that MMP-2 and MMP-9 may
play major roles in the pathogenesis of steroid induced
glaucoma as their levels were decreased in human TM cells
treated with steroid [31]. In a perfused human organ culture
injection of MMP-2 and MMP-9 led to a significantly increased
outflow facility [5]. Decreased extracellular activities of MMPs
were also reported in steroid treated human TM organ and cell
cultures [16]. Altered levels of MMPs have also been described
in the chamber angle and aqueous humor of patients with
primary open angle glaucoma and exfoliation glaucoma
[32,33]. Together these findings suggest the role of MMPs in
the pathophysiology of steroid induced glaucoma as well as in
other forms of glaucoma. In the present study, we found that
overexpression of PLAT upregulated expression of MMP-2, -9
and -13 significantly compared to the levels found in TA only
treated eyes. Similarly, tPA induced MMP-2 and MMP-9
upregulation has been reported in human cerebral
microvascular endothelial cell culture [34] while increased
activity and expression of MMP-9 by recombinant tPA have
also been described in stroke [35,36].
MMP-13 is an interstitial collagenase that degrades collagen
type I, collagen type III and collagen type IV. Collagen types I
and II are the interstitial types that form banded fibrils of the
trabecular core, the basement membrane of the trabecular
beams and loose aggregates in the juxtacanalicular tissue [37].
Type IV collagen is another interstitial type of collagen, which
has been shown to form a fine network around striated fibrils in
the trabecular cores and linkage strands to the basement
membranes [38]. Dexamethasone has been shown to
upregulate collagen type I protein in the organ-cultured
trabecular meshwork [39]. Although the association between
MMP-13 and glaucoma is not strongly established, we
investigated MMP-13 expression because PLAT gene
disruption is known to affect MMP-13 expression in the liver of
animals subjected to CCl(4) injury [40]. tPA induced MMP-13
upregulation in our study suggests that this MMP may also be
involved in degrading ECM collagen in the TM.
Although upregulation of expression of pro-MMPs does not
prove that these enzymes become active as a result of
activation of tPA in the TM, it makes such a mechanism of
action very likely. tPA has however been shown to work
through other non-MMP related pathways in modulating ECM.
For example, tPA mediated ECM modulation can be through
plasmin which can directly degrade ECM components like
laminin, fibronectin and elastin [41,42]. Determination of
whether plasmin directly degrades ECM in the TM in this
animal model will require additional work.
In summary, we have shown that overexpression of PLAT in
TM of mouse eyes can both prevent and reverse the decrease
in outflow facility caused by steroid treatment. The PLAT
mediated increase in outflow facility is associated with
upregulation of MMPs and occurs despite a compensatory
increase in PAI-1 expression. These findings could have
tPA Effect on Outflow Facility
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important therapeutic implications in the management for
steroid induced glaucoma.
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